NCT03905291View on ClinicalTrials.gov

Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

December 26, 2018

Study Completion Date

December 26, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

MT921

Formulated as an injectable solution

DRUG

Placebo

normal saline

Trial Locations (1)

Unknown

Anam Hospital, Seoul

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03905291 - Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects | Biotech Hunter | Biotech Hunter